Home/Pipeline
Program
PreclinicalPhase 1Phase 2Phase 3FiledApproved
Next milestoneCLV-101orevantinibVRX-1 solid tumorsOncology · Small molecule
Label expansion filing 2027
CLV-114tazulimab-cvraMultiple myelomaOncology · Antibody
Earlier-line data H1 2027
CLV-205solekizumabPlaque psoriasisImmunology · Antibody
Pediatric study ongoing
CLV-302trelanemabEarly Alzheimer's diseaseNeuroscience · Antibody
Subcutaneous form in Phase 3
CLV-404calvasiranHyperlipidemiaCardiometabolic · RNA
Outcomes study fully enrolled
CLV-501elvoparvecSpinal muscular atrophyRare Disease · Gene therapy
Long-term follow-up
Pipeline as of September 30, 2026. Programs and data are fictional.